Galderma
As of the edition of 20 October 2026, Galderma runs 10 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 5 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nemolizumab | Ends 2036 (computed from the first US licence) | 2 |
| Methyl aminolevulinate | none listed | 0 |
| Trifarotene | Ends 2031 (patent) | 2 |
A route B row is one company at one target.
Where its trials are
- Skin and connective tissue: 25 trials led
- Immune system: 11 trials led
- Inherited and neonatal: 10 trials led